Insider trade

Officer sold ~$364K of CORT shares in the open market

Traded Nov 25, 2025 · Filed Dec 4, 2025

Why it stands out

Corcept Therapeutics's Chief Development Officer sold $364K of Corcept Therapeutics shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

OfficerIndirect holding$100K–$500K

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$364,070

Shares × reported transaction price

Timing vs results

21 days after results of Nov 4, 2025, 91 days before results of Feb 24, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+2.2%	−0.6%	+2.8%
30 days	−59.4%	+0.3%	−59.7%
90 days	−60.5%	−0.6%	−59.8%
180 days	−15.6%	+10.0%	−25.6%

Past results only. Not a forecast.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.81 to $81.085 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
On November 26, 2025, the Reporting Person filed a Form 4 that inadvertently reported that the 4,500 shares sold were held directly. By this amendment, the Reporting Person corrects such report by reporting that the shares sold were held indirectly by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee as a result of the transfer that occurred on November 17, 2025, now reported in this amendment.
Represents the shares held by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee.